The rapidly changing treatment landscape for lung cancer could soon change again. This morning, Merck (NYSE: MRK) announced that a Phase 3 study called Keynote-407 has succeeded. The trial tested a combination of its immunotherapy pembrolizumab (Keytruda) and chemotherapy in 560 patients just diagnosed with advanced, squamous non-small cell lung cancer. Merck didn’t disclose specifics, […]
Original Article: Ahead of ASCO, Merck Touts Another Win for Lung Cancer Drug Combo